Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches
This study is not yet open for participant recruitment.
Verified by Hadassah Medical Organization, February 2009
First Received: February 1, 2009   Last Updated: February 2, 2009   History of Changes
Sponsor: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00835029
  Purpose

Background: Oral candidiasis is most frequently found among the elderly .It is accompanied with oral pain, irritation, burning sensation. In addition, the altered taste sensation may cause nutrition compromise, which may affect ones diet. Management of superficial oral Candida is usually achieved by treatment with clotrimazole, a fungi static drug which is given five times per day with instruction to slowly suck on it with out the dentures.

Working hypothesis and aims: Management of oral candidiasis is feasible. The major disadvantage of the mode of action now days is the substantively of the drug in the oral cavity and patient compliance. A sustained release varnish which is easily applied on the dentures, which also release the anti fungal drug for at least a day, may overcome some of the pit falls of the treatment applied today.

Based on our past experience, in developing local sustained release varnishes for dental use, we anticipate that we can also formulate a special anti fungal sustained release varnish which will fit the special and unique needs of the elderly population.

Methods: Sustained release varnish will be developed in our laboratory. The kinetics of release (using HPLC) and antifungal activity (Bioassays) will be examined in vitro. The formulation showing the optimal results will be tested on human subjects with oral candidiasis. The efficacy of the varnish will be examined clinically (reduction in symptoms), microbiology (reduction of oral fungal), pharmaceutically (release kinetics in vivo).

Expected results: The clinical out come of one time varnish application will be improved compared to the five times application of lozenges (used today). The severity of the disease should decrease and the healing period should be shorten drastically.

Importance: This is a novel pharmaceutical development of a local application of a dental varnish designed specially to the elderly population


Condition Intervention Phase
Oral Candidiasis
Denture Stomatitis
Drug: clotrimazole ,slow release varnish
Drug: clotrimazole
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Microbial evidence of reduced candida infection [ Time Frame: one and two weeks after inevention ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical evidence for candida infection [ Time Frame: One and two weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2009
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Clotrimazole in a slow release varnish treatment
Drug: clotrimazole ,slow release varnish
clotrimazole,50 mg ,in a slow release varnish formulation for local application on the denture
2: Active Comparator
Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
Drug: clotrimazole
clotrimazole troches 10 mgx5 a day for two weeks arm 1

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults
  • removable denture in mouth
  • diagnosed oral candida

Exclusion Criteria:

  • allergy to clotrimazole
  • immunosuppressed
  • using other antifungi treatment
  • have an active oral ulcerative disease
  • impaired kidny or live functions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00835029

Contacts
Contact: Rakefet Czerninski, DMD 01197226776140 rakefetc@hadassah.org.il
Contact: Rakefet Czerninski, DMD 01197226776151 eran02@bezeqint.net

Locations
Israel
Hdassah medical Organization,
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Rakefet Czerninski, DMD Hadassah Medical Center
  More Information

No publications provided

Responsible Party: : Hadassah Medical Organization ( Dr.Rakefet Czerninski )
Study ID Numbers: 111111
Study First Received: February 1, 2009
Last Updated: February 2, 2009
ClinicalTrials.gov Identifier: NCT00835029     History of Changes
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
oral
candida
denture
clotrimazole
slow releases

Additional relevant MeSH terms:
Mouth Diseases
Anti-Infective Agents
Candidiasis, Oral
Candidiasis
Stomatitis
Clotrimazole
Miconazole
Stomatitis, Denture
Pharmacologic Actions
Mycoses
Anti-Infective Agents, Local
Antifungal Agents
Therapeutic Uses
Stomatognathic Diseases

ClinicalTrials.gov processed this record on February 08, 2010